Uranium Royalty (TSE:URC – Get Free Report) had its price objective decreased by Canaccord Genuity Group from C$6.75 to C$6.50 in a report issued on Tuesday, BayStreet.CA reports. The brokerage currently has a “speculative buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 93.45% from the stock’s previous close.
Uranium Royalty Stock Up 2.4 %
TSE URC traded up C$0.08 on Tuesday, hitting C$3.36. 156,975 shares of the stock were exchanged, compared to its average volume of 202,035. The company has a 50-day moving average price of C$3.00 and a 200-day moving average price of C$3.24. Uranium Royalty has a fifty-two week low of C$2.53 and a fifty-two week high of C$5.05. The company has a market cap of C$408.24 million, a PE ratio of 48.00 and a beta of 1.68.
Uranium Royalty (TSE:URC – Get Free Report) last released its quarterly earnings data on Thursday, September 12th. The company reported C($0.02) EPS for the quarter. Uranium Royalty had a return on equity of 3.83% and a net margin of 20.29%.
Uranium Royalty Company Profile
Uranium Royalty Corp. operates as a pure-play uranium royalty company. It acquires, accumulates, and manages a portfolio of geographically diversified uranium interests. The company has royalty interests in the McArthur River, Cigar Lake / Waterbury Lake, Roughrider, Russell Lake, Russell Lake south, and Dawn Lake projects in Saskatchewan, Canada; Anderson and San Rafael projects in Arizona; Lance and Reno Creek projects in Wyoming; Church Rock and Roca Honda projects in New Mexico; Dewey-Burdock project in South Dakota; Slick Rock project in Colorado; Langer Heinrich project in Namibia; and Michelin project in Newfoundland and Labrador, Canada; Energy Queen and Whirlwind project in Utah; and Workman Creek projects in Arizona.
See Also
- Five stocks we like better than Uranium Royalty
- Why Invest in High-Yield Dividend Stocks?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 5 discounted opportunities for dividend growth investors
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The Significance of Brokerage Rankings in Stock Selection
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Uranium Royalty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uranium Royalty and related companies with MarketBeat.com's FREE daily email newsletter.